Harmony Biosciences stock price target lowered to $62 at Oppenheimer

Harmony Biosciences (HRMY) experienced a clinical setback as its ZYN002 Phase 3 trial for Fragile X syndrome failed to meet its primary endpoint due to a high placebo response, leading Oppenheimer to lower its price target to $62 while maintaining an Outperform rating and significantly reducing success probabilities for other ZYN002 indications. Despite this, Oppenheimer views the resulting stock weakness as a potential buying opportunity, a sentiment supported by the company's strong Q2 2025 EPS beat ($0.92 vs. $0.72 est.), robust financial health, an attractive 8.8x P/E ratio, and other analysts like UBS and Mizuho recently raising their price targets on optimism for Zygel and management confidence.

Analysis

Harmony Biosciences (HRMY) faces a pivotal reassessment following the failure of its ZYN002 Phase 3 RECONNECT trial for Fragile X syndrome (FXS) to meet its primary endpoint, attributed to a high placebo response rate. This clinical setback prompted Oppenheimer to lower its price target to $62 from $70, remove FXS from its financial model, and drastically reduce the probability of success for ZYN002 in 22q deletion syndrome to 20% from a previous 65%. Despite this pipeline derisking, the company's underlying financial health appears strong, evidenced by a balance sheet with more cash than debt, a Q2 2025 earnings per share of $0.92 that beat estimates by 27.78%, and a reported 17.7% revenue growth. This financial strength is coupled with an attractive valuation, with shares trading at a P/E ratio of 8.8x. Analyst sentiment is notably divergent; while Oppenheimer cut its target, it maintained an Outperform rating and views the stock's subsequent weakness as an opportunity. Concurrently, both UBS and Mizuho raised their price targets to $50, with UBS increasing its risk-adjusted peak sales estimate for Zygel, indicating confidence in the existing commercial portfolio irrespective of the ZYN002 outcome.

Key Decisions for Investors

• Investors should weigh the significant clinical pipeline risk from the ZYN002 trial failure against the company's strong fundamentals, including a substantial Q2 EPS beat, an attractive P/E ratio of 8.8x, and a robust balance sheet.
• Monitor future company updates on the ZYN002 program, as the divergence between Oppenheimer's target cut and the target increases from UBS and Mizuho highlights significant uncertainty regarding the asset's future value.
• Consider re-evaluating the stock as a value-oriented investment based on its current earnings power and valuation, rather than a growth story dependent on the now-impaired ZYN002 pipeline, aligning with Oppenheimer's view of the current weakness as a potential opportunity.